{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:34:27Z","timestamp":1774460067011,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy and safety of different antiplatelet in minor strokes or transient ischemic attacks (TIAs) remains controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Embase, Web of Science and the Cochrane Library to identify all eligible articles until 12 September 2024. Efficacy outcomes were all-cause mortality, excellent outcome, functional independence and recurrent stroke. Safety outcomes were any types of bleeding and intracerebral hemorrhage (ICH). The associations were calculated for the overall data by using the odds ratios (ORs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>12 high-quality studies with 10 RCTs and 2 Non-RCTs were included, involving 61,281 patients with minor strokes or TIAs. Ticagrelor + Aspirin was significantly more effective than Clopidogrel + Aspirin in preventing post-stroke neurological dysfunctions (mRS 0\u20131), recurrent stroke and major vascular events for up to 90 days. But Ticagrelor + Aspirin is associated with an increased risk of any bleeding and mild bleeding at 90 days, and there is no significant difference in other bleeding risks. The risk of any bleeding in Dipyridamole + Aspirin is not significantly different from that in Aspirin, and is even significantly lower than in Ticagrelor. Compared with other dual antiplatelet therapies (DAPTs), Dipyridamole + Aspirin had no significant difference in the risk of all-cause mortality and major vascular events during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For minor strokes or TIAs with a low bleeding risk or CYP2C19 loss-of-function alleles, Ticagrelor + Aspirin may be a better choice than Clopidogrel + Aspirin. Due to limited studies, the superiority of Dipyridamole + Aspirin is still difficult to conclude, and further high-quality studies are needed to verify the benefits of Dipyridamole + Aspirin in minor stroke or TIAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42024537462<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1561564","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:28:59Z","timestamp":1742966939000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ticagrelor or dipyridamole plus aspirin may be a promising antiplatelet therapy in patients with minor stroke or transient ischemic attack: a bayesian network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shiran","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke","volume":"374","author":"Amarenco","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/1747493018786616","article-title":"Canadian stroke best Practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018","volume":"13","author":"Boulanger","year":"2018","journal-title":"Int. J. Stroke"},{"key":"B3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jama.2013.7086","article-title":"Medical management after coronary stent implantation: a review","volume":"310","author":"Brilakis","year":"2013","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart association\/American stroke association","volume":"52","author":"Dawn","year":"2021","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jocn.2014.05.038","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke","volume":"22","author":"He","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.5551\/jat.64502","article-title":"Cilostazol plus aspirin vs. Clopidogrel plus aspirin in acute minor stroke or transient ischemic attack","volume":"31","author":"Huang","year":"2024","journal-title":"J. Atheroscler. Thromb."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/nejmoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/STROKEAHA.118.022691","article-title":"Comparative effectiveness of aspirin and clopidogrel versus aspirin in acute minor stroke or transient ischemic attack","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","article-title":"Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis","volume":"135","author":"Pan","year":"2017","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart association\/American stroke association","volume":"50","author":"Powers","year":"","journal-title":"Stroke"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart association\/American stroke association","volume":"50","author":"Powers","year":"","journal-title":"Stroke"},{"key":"B18","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.116.025250","article-title":"Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults","volume":"135","author":"Wang","year":"","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial","volume":"365","author":"Wang","year":"2019","journal-title":"Bmj"},{"key":"B21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1747493017694391","article-title":"2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack","volume":"12","author":"Wang","year":"","journal-title":"Int. J. Stroke"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/circulationaha.114.014791","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes","volume":"132","author":"Wang","year":"2015","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack","volume":"316","author":"Wang","year":"2016","journal-title":"Jama"},{"key":"B26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1474-4422(18)30500-3","article-title":"Stroke in China: advances and challenges in epidemiology, prevention, and management","volume":"18","author":"Wu","year":"2019","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:29:00Z","timestamp":1742966940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1561564"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1561564","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"1561564"}}